• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Mastitis Market Trends

    ID: MRFR/Pharma/3936-CR
    142 Pages
    Rahul Gotadki
    July 2019

    Mastitis Market Research Report Information by Type (Bovine {Contagious Mastitis, Environmental Mastitis and Opportunist Mastitis} and Human {Non-Infectious Mastitis and Infectious Mastitis}), Treatment (Bovine {Antibiotics and Vaccines} and Human {Pain Relievers and Antibiotics}), End User (Veterinary Centers and Hospital & Clinics) - Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Mastitis Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Trends

    Mastitis Market Trends and Future Forecast

    Changes in how people live, eat, and interact in society have made cancer more widespread. Among various types of cancer, breast cancer is the most common in women globally and ranks second overall. In 2018 alone, there were over 2 million new cases of breast cancer worldwide, as reported by the World Cancer Research Fund. Unfortunately, women who have had breast cancer are at a higher risk of developing mastitis, especially during breastfeeding. The increasing number of breast cancer cases globally is a major factor contributing to the growth of the global mastitis market. For instance, in the United States, the Breast Cancer Research Foundation estimated that 266,120 new cases of invasive breast cancer were diagnosed in women in 2018, making it the most common cancer among American women, second only to skin cancer. The impact of breast cancer is not limited to the United States. In the United Kingdom, breast cancer was responsible for approximately 11,563 deaths in 2016, according to Cancer Research UK. On a global scale, Belgium had the highest rate of breast cancer in women in 2017, with a rate of 113.2 per 10,000 breast cancer cases, as reported by the World Cancer Research Fund International. This trend of increasing breast cancer rates worldwide is directly linked to a rise in mastitis cases. As more women experience breast cancer, the occurrences of mastitis, an inflammation of the breast tissue often associated with breastfeeding, are also on the rise. The connection between breast cancer and mastitis emphasizes the need for effective solutions and treatments for mastitis. Understanding the global trends in breast cancer and its consequences, including mastitis, is crucial for healthcare professionals and researchers working to address the challenges posed by these conditions. The increasing prevalence of breast cancer globally underscores the importance of ongoing efforts to develop better diagnostic tools, preventive measures, and treatment options for mastitis and related complications.

    Market Summary

    As per Market Research Future Analysis, the Mastitis Market was valued at USD 23.63 Billion in 2023 and is projected to grow to USD 53.64 Billion by 2032, with a CAGR of 16.73% from 2024 to 2032. The condition primarily affects nursing women and dairy cattle, leading to significant health issues and economic losses in livestock production. Recent innovations include Danone's probiotic supplement Almimama and Zoetis's Protivity® vaccine, aimed at reducing mastitis incidence. The market is driven by rising disease prevalence, product innovations, and increased awareness among dairy producers. However, challenges such as antibiotic resistance and diagnostic difficulties may hinder growth.

    Key Market Trends & Highlights

    The Mastitis Market is witnessing significant growth driven by various factors.

    • Market Size in 2023: USD 23.63 Billion Projected Market Size by 2032: USD 53.64 Billion CAGR from 2024 to 2032: 16.73% Major innovations include Danone's Almimama and Zoetis's Protivity®

    Market Size & Forecast

    2023 Market Size USD 23.63 Billion
    2024 Projected Market Size USD 36.14 Billion
    2032 Projected Market Size USD 53.64 Billion
    CAGR (2024-2032) 16.73%

    Major Players

    <p>Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck Co. &amp; Inc., Pfizer Inc.</p>

    Market Trends

    <p>The increasing prevalence of mastitis in dairy herds underscores the urgent need for effective management strategies to enhance animal welfare and ensure the sustainability of dairy production.</p>

    U.S. Department of Agriculture (USDA)

    Mastitis Market Market Drivers

    Market Growth Projections

    The Global Mastitis Market Industry is poised for substantial growth, with projections indicating a compound annual growth rate (CAGR) of 8.12% from 2025 to 2035. This growth trajectory suggests a robust demand for innovative solutions in mastitis management, driven by factors such as rising dairy consumption and advancements in treatment technologies. The market's expansion reflects the increasing recognition of mastitis as a critical issue affecting dairy production and profitability. As stakeholders across the industry respond to these challenges, the market is likely to witness significant investments and developments in the coming years.

    Growing Focus on Animal Welfare

    The increasing emphasis on animal welfare is reshaping the Global Mastitis Market Industry. Consumers are becoming more conscious of the ethical treatment of animals, which drives dairy producers to adopt practices that ensure the health and well-being of their livestock. This focus on welfare includes the implementation of effective mastitis management strategies, as healthy animals are essential for sustainable production. As the market evolves, producers who prioritize animal welfare are likely to gain a competitive edge, further stimulating demand for mastitis-related products and services.

    Government Initiatives and Support

    Government initiatives aimed at improving animal health and welfare are pivotal in shaping the Global Mastitis Market Industry. Various countries are implementing policies that promote research and development in mastitis management, alongside funding programs for farmers to access better veterinary care. These initiatives not only enhance awareness of mastitis but also encourage the adoption of best practices in dairy farming. As governments recognize the economic implications of mastitis, their support is likely to foster innovation and investment in the sector, contributing to sustained market growth.

    Increasing Demand for Dairy Products

    The global surge in demand for dairy products is a significant factor influencing the Global Mastitis Market Industry. As consumer preferences shift towards dairy consumption, the pressure on dairy farmers to maintain high production levels intensifies. This demand creates an urgent need for effective mastitis management solutions to ensure optimal milk quality and quantity. With projections indicating that the market will grow to 85.3 USD Billion by 2035, the dairy sector is likely to invest heavily in mastitis prevention and treatment strategies, thereby driving market expansion.

    Advancements in Diagnostic Technologies

    Technological innovations in the diagnosis of mastitis are transforming the Global Mastitis Market Industry. Enhanced diagnostic tools, such as molecular techniques and rapid testing methods, facilitate early detection and treatment of mastitis, thereby improving herd health and productivity. These advancements enable farmers to monitor their cattle more effectively, leading to timely interventions that can minimize economic losses. As the industry moves towards more precise and efficient diagnostic solutions, the demand for these technologies is expected to surge, contributing to the overall growth of the market.

    Rising Incidence of Mastitis in Dairy Cattle

    The increasing prevalence of mastitis among dairy cattle is a primary driver of the Global Mastitis Market Industry. In 2024, the market is valued at 36.1 USD Billion, reflecting the urgent need for effective treatment and prevention strategies. Mastitis not only affects milk production but also poses significant economic challenges for dairy farmers. The disease can lead to reduced milk yield and quality, which in turn impacts profitability. As awareness of mastitis management grows, investments in veterinary care and innovative treatments are likely to rise, further propelling market growth.

    Market Segment Insights

    Regional Insights

    Key Companies in the Mastitis Market market include

    Industry Developments

    • A new Biological Development Centre (BDC) at Boehringer Ingelheim's research development locations in Biberach, Germany, was revealed in June 2018 with a 230-million-euro investment. The BDC will be the company's first BDC.
    • Tavocept, an experimental novel medication developed by BioNumerik Pharmaceuticals, was approved by the Food and Drug Administration in June 2017 for use in both cancer and non-oncology purposes.
    • Keytruda, developed by Merck & Co., was authorized by the FDA in May 2017 to treat adult and pediatric individuals with recently treated advanced or metastatic or metastatic solid tumors with high microsatellite instability (MSI-H) mismatch repair deficiency.

    Future Outlook

    Mastitis Market Future Outlook

    <p>The Global Mastitis Market is projected to grow at 8.12% CAGR from 2024 to 2032, driven by advancements in treatment technologies and increasing dairy production.</p>

    New opportunities lie in:

    • <p>Develop innovative mastitis detection devices using AI and IoT technologies. Expand product lines to include organic and antibiotic-free treatment options. Invest in educational programs for farmers on mastitis prevention and management.</p>

    <p>By 2035, the Mastitis Market is expected to achieve substantial growth, reflecting evolving industry standards and consumer demands.</p>

    Market Segmentation

    Report Overview

    • Recent Developments
    • A new Biological Development Centre (BDC) at Boehringer Ingelheim's research development locations in Biberach
    • Germany
    • was revealed in June 2018 with a 230-million-euro investment. The BDC will be the company's first BDC.
    • Tavocept
    • an experimental novel medication developed by BioNumerik Pharmaceuticals
    • was approved by the Food and Drug Administration in June 2017 for use in both cancer and non-oncology purposes.
    • Keytruda
    • developed by Merck & Co.
    • was authorized by the FDA in May 2017 to treat adult and pediatric individuals with recently treated advanced or metastatic or metastatic solid tumors with high microsatellite instability (MSI-H) mismatch repair deficiency.

    Market Segmentation

    • Mastitis Market
    • by Type
    • Bovine
    • Contagious Mastitis
    • Environmental Mastitis
    • Opportunist Mastitis
    • Human
    • Non-Infectious Mastitis
    • Infectious Mastitis
    • Mastitis Market
    • by Region
    • Americas
    • North America
    • US
    • Canada
    • Latin America
    • Europe
    • Western Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Saudi Arabia
    • United Arab Emirates
    • Kuwait
    • Oman
    • Qatar
    • Rest of Middle East
    • Mastitis Market
    • by End User
    • Veterinary Centers
    • Hospital & Clinics
    • Mastitis Market
    • by Treatment
    • Bovine
    • Antibiotics
    • Vaccines
    • Human
    • Pain Relievers
    • Antibiotics

    Report Scope

    Attribute/MetricDetails
    Market Size 202323.63 (USD Billion)
    Market Size 202436.14 (USD Billion)
    Market Size 203253.64 (USD Billion)
    Compound Annual Growth Rate (CAGR)16.73 % (2024 - 2032)
    Report CoverageRevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year2023
    Market Forecast Period2024 - 2032
    Historical Data2018-2022
      Geographies Covered  North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors  Bayer AG (Germany), Oncothyreon Inc (US), OncoGenex (US), Apthera Inc. (UK), Zoetis Inc. (US), Boehringer Ingelheim GmbH (Germany), Merck Co. & Inc. (US), Astellas Pharma Inc. (Japan), Pfizer Inc. (US), Novartis AG (Switzerland), Sanofi SA (France), and F. Hoffmann-La Roche AG (Switzerland).
      Key Market Opportunities  New product launches and R&D Amongst major key Players
      Key Market Drivers·  Rising cases of breast cancer Increasing rate of pregnancy ·  Unhygienic barn conditions causing contagious mastitis in bovines

     

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    At what CAGR is the mastitis market projected to grow in the forecast period (2024-2032)?

    Mastitis market projected to grow at approximately 16.73% CAGR during the assessment period (2024-2032).

    How much is the mastitis market worth in the future?

    The valuation of the mastitis market is estimated to increase to USD 53.64 Bn by the end of 2032.

    What are the major tailwinds pushing the growth of the global mastitis market?

    Increasing need for better treatments and government funding support for R&amp;D are major tailwinds pushing the growth of the global mastitis market.

    Which region holds the largest share in the global mastitis market?

    North America holds the largest share in the global mastitis market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global mastitis market?

    Novartis AG (Switzerland), Pfizer (U.S.), Oncogenex (U.S.), BioNumerik Pharmaceuticals (U.S.), Apthera Inc. (U.K), Oncothyreon Inc. (US), Bipar Sciences (U.S.), Astellas (Japan), Puma Biotechnology (U.S.), Eli Lilly and Company (U.S.), Sanofi S.A. (U.S.), AstraZeneca (UK), GlaxoSmithKline (U.K), F. Hoffmann-La Roche (Switzerland), Genentech (U.S), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries (Israel), Gilead Sciences, Inc. (U.S.), and Accord Healthcare, Inc. (U.S.), are some of the top players operating in the global mastitis market.

    1. --- '1 Report Prologue
    2. Market Introduction
      1. Definition 19
      2. Scope of the Study 19
      3. Research Objective 19
      4. Assumptions & Limitations 19
        1. Assumptions 19
        2. Limitations 19
        3. Market Structure 20
    3. Research Methodology
      1. Primary Research Methodology 22
      2. Secondary Research Methodology 24
      3. Market Size Estimation 25
      4. Forecast Model 25
    4. Market Dynamics
      1. Introduction 27
      2. Drivers 28
        1. Rising Cases of Breast Cancer 28
        2. Increasing Rate of Pregnancy 28
        3. Unhygienic Barn Conditions Causing Contagious Mastitis in Bovines 28
      3. Restraints 29
        1. Lack of Awareness 29
        2. Complications in Diagnosis due to Similar Symptoms of Breast Cancer & Mastitis 29
      4. Opportunity 29
        1. Entering Developing Economies 29
      5. Macroeconomics 29
        1. Trends in Mastitis 30
    5. Market Factor Analysis
      1. Porter’s Five Forces Model 32
        1. Bargaining Power of Suppliers 32
        2. Bargaining Power of Buyers 33
        3. Threat of New Entrants 33
        4. Threat of Substitutes 33
        5. Intensity of Rivalry 33
      2. Value Chain Analysis 34
        1. R&D & Designing 34
        2. Manufacturing 34
        3. Distribution & Sales 34
        4. Post-Sales Services 34
      3. Investment Opportunities 35
      4. Price Analysis 35
    6. Global Mastitis Market, By Type
      1. Introduction 37
      2. Bovine 38
        1. Contagious Mastitis 38
        2. Environmental Mastitis 39
        3. Opportunist Mastitis 39
      3. Human 40
        1. Non-Infectious Mastitis 40
        2. Infectious Mastitis 41
    7. Global Mastitis Market, By Treatment
      1. Introduction 43
      2. Bovine 44
        1. Antibiotics 44
        2. Vaccines 44
      3. Human 45
        1. Pain Relievers 45
        2. Antibiotics 45
    8. Global Mastitis Market, By End User
      1. Introduction 47
      2. Veterinary Centers 48
      3. Hospital & Clinics 48
    9. Global Mastitis Market, By Region
      1. Introduction 50
      2. Americas 51
        1. North America 54
        2. South America 60
      3. Europe 62
        1. Western Europe 64
        2. Eastern Europe 79
      4. Asia-Pacific 81
        1. Japan 83
        2. China 85
        3. India 87
        4. Australia 89
        5. South Korea 91
        6. Rest of Asia-Pacific 93
      5. Middle East & Africa 95
        1. Saudi Arabia 97
        2. United Arab Emirates 99
        3. Kuwait 101
        4. Oman 103
        5. Qatar 105
        6. Rest of Middle East 107
    10. Competitive Landscape
      1. Competitive Scenario 110
        1. Introduction 110
    11. Company Profiles
      1. Bayer AG 113
        1. Company Overview 113
        2. Financial Overview 113
        3. Products Offering 114
        4. Key Developments 114
        5. SWOT Analysis 114
        6. Key Strategy 114
      2. BioNumerik Pharmaceuticals Inc 115
        1. Company Overview 115
        2. Financial Overview 115
        3. Products/Services Offered 115
        4. Key Developments 115
        5. SWOT Analysis 116
        6. Key Strategy 116
      3. Oncothyreon Inc 117
        1. Company Overview 117
        2. Financial Overview 117
        3. Products/Services Offered 117
        4. Key Developments 117
        5. SWOT Analysis 118
        6. Key Strategy 118
      4. Oncogenex 119
        1. Company Overview 119
        2. Financial Overview 119
        3. Products/Services Offered 119
        4. Key Developments 119
        5. SWOT Analysis 119
        6. Key Strategy 120
      5. Apthera Inc. 121
        1. Company Overview 121
        2. Financial Overview 121
        3. Products/Services Offered 121
        4. Key Developments 121
        5. SWOT Analysis 121
        6. Key Strategy 122
      6. Zoetis Inc 123
        1. Company Overview 123
        2. Financial Overview 123
        3. Products/Services Offered 124
        4. Key Developments 124
        5. SWOT Analysis 124
        6. Key Strategy 124
      7. Boehringer Ingelheim GmbH 125
        1. Company Overview 125
        2. Financial Overview 125
        3. Products/Services Offered 126
        4. Key Developments 126
        5. SWOT Analysis 126
        6. Key Strategy 126
      8. Merck Co. & Inc 127
        1. Company Overview 127
        2. Financial Overview 127
        3. Products/Services Offered 128
        4. Key Developments 128
        5. SWOT Analysis 128
        6. Key Strategy 128
      9. Astellas Pharma Inc 129
        1. Company Overview 129
        2. Financial Overview 129
        3. Products/Services Offered 130
        4. Key Developments 130
        5. SWOT Analysis 130
        6. Key Strategy 130
      10. Pfizer Inc. 131
        1. Company Overview 131
        2. Financial Overview 131
        3. Products/Services Offered 132
        4. Key Developments 132
        5. SWOT Analysis 132
        6. Key Strategy 132
      11. Novartis AG 133
        1. Company Overview 133
        2. Financial Overview 133
        3. Products/Services Offered 134
        4. Key Developments 134
        5. SWOT Analysis 134
        6. Key Strategy 134
      12. Sanofi SA 135
        1. Company Overview 135
        2. Financial Overview 135
        3. Products/Services Offered 136
        4. Key Developments 136
        5. SWOT Analysis 136
        6. Key Strategy 136
      13. F. Hoffmann-La Roche AG 137
        1. Company Overview 137
        2. Financial Overview 137
        3. Products/Services Offered 138
        4. Key Developments 138
        5. SWOT Analysis 138
        6. Key Strategy 138
    12. Appendix
      1. Discussion Blue Print 140
      2. References 141
    13. List of Tables and Figures
      1. 13 List of Tables
      2. TABLE 1 MARKET SYNOPSIS 17
      3. TABLE 2 PRIMARY INTERVIEWS 23
      4. TABLE 3 GLOBAL MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 37
      5. TABLE 4 GLOBAL MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 38
      6. TABLE 5 GLOBAL MASTITIS MARKET FOR BOVINE, BY REGION 2020–2027 (USD MILLION) 38
      7. TABLE 6 GLOBAL MASTITIS MARKET FOR CONTAGIOUS MASTITIS, BY REGION 2020–2027 (USD MILLION) 38
      8. TABLE 7 GLOBAL MASTITIS MARKET FOR ENVIRONMENTAL MASTITIS, BY REGION 2020–2027 (USD MILLION) 39
      9. TABLE 8 GLOBAL MASTITIS MARKET FOR OPPORTUNIST MASTITIS, BY REGION 2020–2027 (USD MILLION) 39
      10. TABLE 9 GLOBAL MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 40
      11. TABLE 10 GLOBAL MASTITIS MARKET FOR HUMAN, BY REGION 2020–2027 (USD MILLION) 40
      12. TABLE 11 GLOBAL MASTITIS MARKET FOR NON–INFECTIOUS MASTITIS, BY REGION 2020–2027 (USD MILLION) 40
      13. TABLE 12 GLOBAL MASTITIS MARKET FOR INFECTIOUS MASTITIS, BY REGION 2020–2027 (USD MILLION) 41
      14. TABLE 13 GLOBAL MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 43
      15. TABLE 14 GLOBAL MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 44
      16. TABLE 15 GLOBAL MASTITIS MARKET FOR ANTIBIOTICS, BY REGION TYPE 2020–2027 (USD MILLION) 44
      17. TABLE 16 GLOBAL MASTITIS MARKET FOR VACCINES, BY REGION 2020–2027 (USD MILLION) 44
      18. TABLE 17 GLOBAL MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 45
      19. TABLE 18 GLOBAL MASTITIS MARKET FOR PAIN RELIEVERS, BY REGION TYPE 2020–2027 (USD MILLION) 45
      20. TABLE 19 GLOBAL MASTITIS MARKET FOR ANTIBIOTICS, BY REGION 2020–2027 (USD MILLION) 45
      21. TABLE 20 GLOBAL MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 47
      22. TABLE 21 GLOBAL MASTITIS MARKET FOR VETERINARY CENTRES, BY REGION 2020–2027 (USD MILLION) 48
      23. TABLE 22 GLOBAL MASTITIS MARKET FOR HOSPITAL & CLINICS, BY REGION 2020–2027 (USD MILLION) 48
      24. TABLE 23 GLOBAL MASTITIS MARKET, BY REGION 2020–2027 (USD MILLION) 51
      25. TABLE 24 AMERICAS MASTITIS MARKET, BY REGION 2020–2027 (USD MILLION) 51
      26. TABLE 25 AMERICAS MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 52
      27. TABLE 26 AMERICAS MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 52
      28. TABLE 27 AMERICAS MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 52
      29. TABLE 28 AMERICAS MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 52
      30. TABLE 29 AMERICAS MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 53
      31. TABLE 30 AMERICAS MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 53
      32. TABLE 31 AMERICAS MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 53
      33. TABLE 32 NORTH AMERICA MASTITIS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 54
      34. TABLE 33 NORTH AMERICA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 54
      35. TABLE 34 NORTH AMERICA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 54
      36. TABLE 35 NORTH AMERICA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 55
      37. TABLE 36 NORTH AMERICA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 55
      38. TABLE 37 NORTH AMERICA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 55
      39. TABLE 38 NORTH AMERICA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 55
      40. TABLE 39 NORTH AMERICA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 56
      41. TABLE 40 US MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 56
      42. TABLE 41 US MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 56
      43. TABLE 42 US MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 56
      44. TABLE 43 US MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 57
      45. TABLE 44 US MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 57
      46. TABLE 45 US MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 57
      47. TABLE 46 US MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 57
      48. TABLE 47 CANADA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 58
      49. TABLE 48 CANADA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 58
      50. TABLE 49 CANADA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 58
      51. TABLE 50 CANADA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 58
      52. TABLE 51 CANADA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 59
      53. TABLE 52 CANADA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 59
      54. TABLE 53 CANADA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 59
      55. TABLE 54 SOUTH AMERICA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 60
      56. TABLE 55 SOUTH AMERICA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 60
      57. TABLE 56 SOUTH AMERICA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 60
      58. TABLE 57 SOUTH AMERICA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 60
      59. TABLE 58 SOUTH AMERICA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 61
      60. TABLE 59 SOUTH AMERICA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 61
      61. TABLE 60 SOUTH AMERICA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 61
      62. TABLE 61 EUROPE MASTITIS MARKET, BY REGION 2020–2027 (USD MILLION) 62
      63. TABLE 62 EUROPE MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 62
      64. TABLE 63 EUROPE MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 62
      65. TABLE 64 EUROPE MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 63
      66. TABLE 65 EUROPE MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 63
      67. TABLE 66 EUROPE MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 63
      68. TABLE 67 EUROPE MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 63
      69. TABLE 68 EUROPE MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 64
      70. TABLE 69 WESTERN EUROPE MASTITIS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 64
      71. TABLE 70 WESTERN EUROPE MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 65
      72. TABLE 71 WESTERN EUROPE MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 65
      73. TABLE 72 WESTERN EUROPE MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 65
      74. TABLE 73 WESTERN EUROPE MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 65
      75. TABLE 74 WESTERN EUROPE MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 66
      76. TABLE 75 WESTERN EUROPE MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 66
      77. TABLE 76 WESTERN EUROPE MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 66
      78. TABLE 77 GERMANY MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 67
      79. TABLE 78 GERMANY MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 67
      80. TABLE 79 GERMANY MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 67
      81. TABLE 80 GERMANY MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 67
      82. TABLE 81 GERMANY MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 68
      83. TABLE 82 GERMANY MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 68
      84. TABLE 83 GERMANY MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 68
      85. TABLE 84 FRANCE MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 69
      86. TABLE 85 FRANCE MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 69
      87. TABLE 86 FRANCE MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 69
      88. TABLE 87 FRANCE MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 69
      89. TABLE 88 FRANCE MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 70
      90. TABLE 89 FRANCE MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 70
      91. TABLE 90 FRANCE MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 70
      92. TABLE 91 UK MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 71
      93. TABLE 92 UK MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 71
      94. TABLE 93 UK MASTITIS MARKET FOR HUMAN, BY TYPE 2020&'

    Mastitis Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027